X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Interest cost on Merind takeover pulls down Wockhardt net - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Feb 29, 2000

    Interest cost on Merind takeover pulls down Wockhardt net

    Wockhardt has declared impressive operations results for the 18–month period ended December 1999. The company extended its year to 18 months primarily since it has changed its year ending from June to December as well as de–merged its non-pharmaceutical businesses into a separate company – Wockhardt Life Sciences. The current results include the performance of the non–pharma business too.

    (Rs m) Dec 1999
    (18 months)
    June 1998
    (12 months)
    Change
    Sales 8,625.0 4,035.0 113.8%
    Other Income 63.0 81.0 -22.2%
    Expenditure 7,067.0 3,252.0 117.3%
    Interest 260.0 - 0.0%
    Depreciation 246.0 128.0 92.2%
    Profit before Tax 1,099.0 736.0 49.3%
    Tax 43.0 28.0 53.6%
    Profit after Tax/(Loss) 1,056.0 708.0 49.2%
    Net profit margin (%) 12.2% 17.5%  

    Wockhardt was started in 1973 as a closely held company. The company went public in Dec 1992. It is ranked fifth by local sales in Indian pharma sector along with its 97% subsidiary, Merind. It also has subsidiaries in the UK and USA, which have a presence in generic markets.

    If one were to annualise the results the net sales have grown by 43% while the operating profits have gone up by 33%. As a focussed pharma company, in the future, growth rates for sales and PAT will improve further. This is because the de–merged company Wockhardt will have 80% of the profits and only 32% of the assets.

    The company has grown among the fastest among top 10 pharma companies and ranks fifth in ORG’s retail audit. It’s current product portfolio is strong and most of its brands are either market leaders or enjoy a dominant position. Its top 5 brands are expected to contribute only 29% of its sales. Almost 30% of its total pharma sales come from products launched over the last five years.

    The company gets only 12% of its revenues from products under Drug Price Control Order (DPCO). This low percentage is because new product and/or technology introductions are exempt from the DPCO category for the first five years. Over the last eighteen months too the company has introduced 33 products in the domestic market including Kefstar an oral cephalosporin and the Biovac–B, the Hepatitis B vaccine (in alliance with a German company).

    The company is focussing on the US based generic market and has already filed 4 Abbreviated New Drug Applications (for formulations) and 7 Drug Master Files (for bulk drugs). Each ANDA filing costs around half a million dollars. Besides, the company already has a tie up with Sidmak Labs USA in place. The introduction of ranitidine however seems like a move to test the US generic market rather than with any commercial intention in mind since the company was not the first to introduce the generic product in the US market.

    Wockhardt’s DPP (dexo-propoxy-phene) was revised upwards by 25% in Aug 99. The company ranks at number two in the manufacture of DPP worldwide. Besides, DPP is used for its key brand, Proxyvon, which accounts for more than Rs 500m sales in India. Thus the benefit of a corresponding price revision in the end product prices (Proxyvon) will further improve pharma profits in FY2000.

    Perhaps the only grey area is the higher interest charges. This is because the company borrowed funds while taking over Merind. While the business of Merind has been integrated the legal merger is still some time away. Thus while the cost of debt is reflected in Wockhardt’s books, the revenues and profits of Merind are not.

    Interest costs of Rs. 260 million along with extraordinary write off amounting to Rs.43 million (on account of bad debts accruing from the exports to Russia) have pulled down the net margins in the current year.

    Market View:
    Analysts have rated Wockhardt as a buy primarily due to the de–merger of the pharma business which will improve the profitability of the business since the pharma business has only 32% of the assets of the company but reports almost 80% of the net profit. Besides, the pharmaceutical business is itself an extremely strong business and is expected to do very well despite the introduction of product patents in 2005.

     

     

    Equitymaster requests your view! Post a comment on "Interest cost on Merind takeover pulls down Wockhardt net". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CAROL INFO SHARE PRICE


    Mar 9, 2012 (Close)

    TRACK CAROL INFO

    • Track your investment in CAROL INFO with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS